Fisher & Paykel Healthcare Corporation Ltd (FPH.AU) saw its stock soar 5.13% in Thursday's trading session, outperforming the broader market. The surge comes amid positive analyst commentary on the company's positioning in the face of potential U.S. tariffs.

According to a recent broker note from Macquarie Group, Fisher & Paykel Healthcare is relatively well-positioned compared to some of its Australian healthcare peers. The company's products, manufactured in Mexico, are compliant under the USMCA (United States-Mexico-Canada Agreement) and currently avoid the steep 25% tariffs imposed on other regions by the U.S. This advantageous position could protect the company's margins and competitiveness in the important U.S. market.

Furthermore, Macquarie highlighted potential upside for Fisher & Paykel Healthcare if respiratory devices and apparatus are exempted from tariffs under the Nairobi Protocol, as implemented through the Harmonised Tariff Schedule. The broker maintains an "outperform" rating on Fisher & Paykel Healthcare, reflecting confidence in the company's ability to navigate the challenging global trade environment. Investors appear to be reacting positively to this assessment, driving up the stock price in anticipation of sustained performance.